Israel seeks first excessive pricing penalty

Israel’s Competition Authority plans to fine a pharmaceutical company €2.3 million for charging excessive prices for a life-saving genetic disorder medication, which would mark the first time the enforcer has issued sanctions for such an infringement.


Get unlimited access to all Global Competition Review content